Mirum Pharmaceuticals

Pharma

Ipsen's liver disease drug Bylvay fails biliary atresia trial

Ipsen has reported the failure of liver disease med Bylvay in a phase 3 study that was designed to expand its patient population into biliary atresia.

Kevin Dunleavy Jul 24, 2026 11:00am

Mirum's Ctexli scores FDA approval in rare metabolic disorder

Feb 21, 2025 3:30pm

Mirum gets 2nd indication for blockbuster hopeful Livmarli

Mar 13, 2024 6:20pm

Travere cuts 20% of workforce, aims to win full nod for Filspari

Dec 5, 2023 11:26am

Mirum ponies up $445M for 2 Travere liver disease drugs

Jul 18, 2023 8:00am

Ipsen pays $952M to acquire Albireo and liver disease med Bylvay

Jan 9, 2023 10:05am